Rachel Schiff
#157,527
Most Influential Person Now
Researcher
Rachel Schiff's AcademicInfluence.com Rankings
Rachel Schiffcomputer-science Degrees
Computer Science
#8767
World Rank
#9218
Historical Rank
Database
#5765
World Rank
#5981
Historical Rank
Download Badge
Computer Science
Rachel Schiff's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Rachel Schiff Influential?
(Suggest an Edit or Addition)Rachel Schiff's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. (2004) (1172)
- Mechanisms of endocrine resistance in breast cancer. (2011) (1018)
- Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. (2003) (811)
- Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. (1998) (708)
- The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo (2011) (554)
- Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. (2008) (512)
- Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. (2005) (500)
- Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. (2005) (482)
- Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. (2008) (474)
- Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. (2005) (464)
- Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance (2004) (446)
- Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. (2005) (439)
- HER2: biology, detection, and clinical implications. (2011) (416)
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer (2015) (405)
- A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis (2012) (391)
- A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. (2013) (374)
- Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response. (2003) (343)
- Estrogen-receptor biology: continuing progress and therapeutic implications. (2005) (343)
- MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. (2014) (321)
- Au Nanomatryoshkas as Efficient Near-Infrared Photothermal Transducers for Cancer Treatment: Benchmarking against Nanoshells (2014) (310)
- Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase (2011) (277)
- Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer (2010) (240)
- Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. (2006) (240)
- Neoadjuvant trastuzumab induces apoptosis in primary breast cancers (2005) (239)
- Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation (2011) (233)
- Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. (2011) (231)
- Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. (2000) (220)
- Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. (2013) (219)
- Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. (1999) (205)
- Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer. (1999) (200)
- Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. (2007) (198)
- Targeting HER2 for the treatment of breast cancer. (2015) (195)
- Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer (2013) (195)
- Gefitinib or Placebo in Combination with Tamoxifen in Patients with Hormone Receptor–Positive Metastatic Breast Cancer: A Randomized Phase II Study (2011) (192)
- Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes (2010) (190)
- Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. (2003) (189)
- Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer (2007) (184)
- Estrogen receptor: current understanding of its activation and modulation. (2001) (179)
- Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. (2006) (166)
- Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. (2006) (163)
- A 32,000-dalton nucleic acid-binding protein from avian retravirus cores possesses DNA endonuclease activity. (1978) (161)
- Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo. (2010) (156)
- An epigenomic approach to therapy for tamoxifen-resistant breast cancer (2014) (155)
- β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib (2011) (154)
- Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators (2005) (151)
- Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. (2018) (142)
- Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. (2003) (142)
- Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth (2002) (134)
- Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities (2007) (129)
- Towards personalized treatment for early stage HER2-positive breast cancer (2019) (127)
- Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. (2008) (127)
- Cancer Cells Resistant to Therapy Promote Cell Surface Relocalization of GRP78 Which Complexes with PI3K and Enhances PI(3,4,5)P3 Production (2013) (124)
- Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. (2005) (117)
- Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers (2014) (115)
- Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications (2013) (112)
- Molecular profiles of progesterone receptor loss in human breast tumors (2009) (108)
- FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer (2016) (106)
- Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells (2010) (104)
- Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype (2008) (101)
- The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth (2006) (96)
- Sphingosine Kinase 1 Induces Tolerance to Human Epidermal Growth Factor Receptor 2 and Prevents Formation of a Migratory Phenotype in Response to Sphingosine 1-Phosphate in Estrogen Receptor-Positive Breast Cancer Cells (2010) (94)
- Estrogen-mediated down-regulation of E-cadherin in breast cancer cells. (2003) (92)
- Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes. (2016) (88)
- Imaging Biomarkers Predict Response to Anti-HER2 (ErbB2) Therapy in Preclinical Models of Breast Cancer (2009) (84)
- The changing role of ER in endocrine resistance. (2015) (83)
- HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade. (2019) (83)
- Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. (2011) (81)
- Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. (2013) (79)
- Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy (2015) (79)
- Embryonic transcription factor SOX9 drives breast cancer endocrine resistance (2017) (79)
- HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer (2017) (79)
- Sub-100nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors. (2014) (74)
- FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer (2019) (74)
- Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer (2014) (72)
- Endocrinology and hormone therapy in breast cancer: New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer (2005) (71)
- The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer (2017) (71)
- Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis. (2018) (69)
- Role of the Estrogen Receptor Coactivator AIB 1 ( SRC-3 ) and HER-2 / neu in Tamoxifen Resistance in Breast Cancer (2003) (68)
- Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells (2015) (66)
- Pathway-Centric Integrative Analysis Identifies RRM2 as a Prognostic Marker in Breast Cancer Associated with Poor Survival and Tamoxifen Resistance123 (2014) (66)
- Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase (2014) (66)
- HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. (2020) (65)
- Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer (2018) (63)
- HER 2: Biology, Detection, and Clinical Implications (2011) (63)
- PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. (2013) (59)
- Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer (2018) (59)
- The Dynamics of Estrogen Receptor Status in Breast Cancer: Re-shaping the Paradigm (2007) (58)
- Cytoplasmic Estrogen Receptor in Breast Cancer (2011) (57)
- Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis (2015) (56)
- Microscaled proteogenomic methods for precision oncology (2019) (55)
- Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance (2020) (55)
- Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance (2014) (53)
- Compartmentalized Ras Proteins Transform NIH 3T3 Cells with Different Efficiencies (2010) (53)
- Upregulation of PKC-δ contributes to antiestrogen resistance in mammary tumor cells (2005) (52)
- Mouse retrotransposons: a cellular reservoir of long terminal repeat (LTR) elements with diverse transcriptional specificities. (1991) (51)
- Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations (2005) (50)
- De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance. (2017) (49)
- Virus-coded origin of a 32,000-dalton protein from avian retrovirus cores: structural relatedness of p32 and the beta polypeptide of the avian retrovirus DNA polymerase (1978) (47)
- Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience. (2005) (46)
- The FBXW2–MSX2–SOX2 axis regulates stem cell property and drug resistance of cancer cells (2019) (45)
- Upregulation of PKC-delta contributes to antiestrogen resistance in mammary tumor cells. (2005) (44)
- Systemic mirnas as potential biomarkers for malignancy (2012) (43)
- TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. (2011) (40)
- Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers (2016) (39)
- Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance (2019) (38)
- Transcriptional activation of mouse retrotransposons in vivo: specific expression in steroidogenic cells in response to trophic hormones. (1991) (38)
- The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. (2021) (37)
- Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer (2016) (37)
- Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells (2009) (36)
- Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer (2018) (36)
- Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance (2016) (36)
- The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance (2018) (36)
- Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer (2019) (33)
- A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. (2019) (33)
- Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies (2012) (31)
- Expression and cellular localization of uterine side-chain cleavage cytochrome P450 messenger ribonucleic acid during early pregnancy in mice. (1993) (29)
- Photo activation of HPPH encapsulated in “Pocket” liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts (2014) (29)
- A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer (2019) (28)
- Aromatase inhibitors: Future directions (2005) (27)
- Amplification and over‐expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells (2014) (27)
- Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 weeks in patients with HER2 overexpressing breast cancer (2015) (26)
- SGK3 is associated with estrogen receptor expression in breast cancer (2012) (26)
- TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer (2019) (25)
- Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy (2019) (25)
- A Noncompetitive Small Molecule Inhibitor of Estrogen-regulated Gene Expression and Breast Cancer Cell Growth That Enhances Proteasome-dependent Degradation of Estrogen Receptor α* (2010) (25)
- New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. (2003) (24)
- Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis. (2010) (24)
- Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (24)
- Local regulation within the female reproductive system and upon embryonic implantation: identification of cells expressing proenkephalin A. (1990) (23)
- The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. (2014) (23)
- Resistance to Anti-HER2 Therapies in Breast Cancer. (2015) (22)
- Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis. (2008) (22)
- AhR ligand aminoflavone suppresses α6‐integrin–Src–Akt signaling to attenuate tamoxifen resistance in breast cancer cells (2018) (22)
- Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium (2010) (21)
- Partial phosphorylation in vivo of the avian retrovirus pp32 DNA endonuclease (1980) (21)
- Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs) (2003) (21)
- Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition (2020) (20)
- Amplification of TLK2 Induces Genomic Instability via Impairing the G2–M Checkpoint (2016) (19)
- The pathophysiology of murine retrovirus-induced leukemias. (1986) (19)
- GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer (2018) (18)
- Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. (2020) (17)
- PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells (2017) (17)
- Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the tamoxifen-bound estrogen receptor. (2003) (15)
- Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of HER2-positive breast cancer patients (2013) (15)
- Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP. (2020) (14)
- The Importance of the Estrogen Receptor in Breast Cancer (2002) (14)
- Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis (2019) (14)
- More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response (2011) (14)
- Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis (2021) (14)
- HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC006/023 and PAMELA trials. (2018) (14)
- Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T) or anastrozole (A) in hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2009) (13)
- Breast Cancer Research and Treatment 2001 Reviewers (2004) (12)
- Trastuzumab-Resistant HER2+ Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) Inhibition (2014) (11)
- Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer. (2015) (11)
- Breast Cancer Endocrine Resistance (2003) (11)
- Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity (2020) (10)
- Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance (2020) (10)
- Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer (2004) (10)
- Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells (2015) (9)
- Akt-dependent phosphorylation on AIB1 serine 967 contributes to breast cancer tamoxifen resistance. (2009) (9)
- Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. (2021) (8)
- Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine. (2018) (7)
- Molecular Mechanisms of Endocrine Resistance (2018) (7)
- A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer (2021) (6)
- The 3D Genomic Landscape of Differential Response to EGFR/HER2 Inhibition in Endocrine-Resistant Breast Cancer Cells. (2020) (5)
- Abstract 3091: A sumoylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis (2012) (5)
- Abstract P4-03-05: AP-1 as a potential mediator of resistance to the cyclin-dependent kinase (CDK) 4/6-inhibitor palbociclib in ER-positive endocrine-resistant breast cancer (2018) (4)
- Advances in Brief Estrogen-mediated Down-Regulation of E-cadherin in Breast Cancer Cells 1 (2003) (4)
- Abstract GS2-01: High levels of interferon-response gene signatures are associated withde novoand acquired resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (4)
- New insight into estrogen receptor-α function and its implication for endocrine therapy resistance in breast cancer (2005) (4)
- PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T-refractory metastatic breast cancer (BC): A correlative analysis of the EGF104900 phase III trial. (2018) (4)
- Abstract 1911: HER2 L755S mutation is associated with acquired resistance to lapatinib and neratinib, and confers cross-resistance to tucatinib in HER2-positive breast cancer models (2020) (4)
- A multiparameter classifier to predict response to lapatinib plus trastuzumab (LT) without chemotherapy in HER2+ breast cancer (BC). (2020) (3)
- Advances in Brief Expression of Wild-Type Estrogen Receptor b and Variant Isoforms in Human Breast Cancer 1 (1999) (3)
- Development of Acneiform Rash Does Not Predict Response to Lapatinib Treatment in Patients with Breast Cancer (2013) (3)
- NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer (2022) (3)
- Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (2018) (3)
- Gene Expression Signatures of PI3K Signaling Are Associated with Low ER Levels and the Luminal B Subtype in Breast Cancer Cell Lines and Human Tumors, and in Patients Predicts Poor Outcome. (2009) (3)
- P5-21-01: A Renewable Tissue Resource of Phenotypically Stable Human Breast Cancer Xenografts for Preclinical Studies. (2011) (3)
- Molecular biology (pre-clinical) (2012) (3)
- Abstract 319: Role of GPR110 on tumorigenesis and metastasis in HER2+ breast cancer in the context of anti-HER2 drug resistance (2016) (3)
- Management of hormone receptor–positive, human epidermal growth factor 2–negative metastatic breast cancer (2021) (3)
- Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells (2022) (2)
- Coordinate Enhancer Reprogramming by GATA3 and AP1 Promotes Phenotypic Plasticity to Achieve Breast Cancer Endocrine Resistance (2019) (2)
- Restoring order at the cell cycle border: Co-targeting CDK4/6 and CDK2. (2021) (2)
- Abstract S4-01: A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models (2017) (2)
- Abstract PD3-09:HER2 L755Smutation is acquired upon resistance to lapatinib and neratinib and confers cross-resistance to tucatinib and trastuzumab in HER2-positive breast cancer cell models (2021) (2)
- Tamoxifen's agonist effect on breast cancer growth is mediated by activation of EGFR/HER-2 with preservation of its antagonist effect on ER-dependent gene expression. (2004) (2)
- New Mechanisms of Signal Transduction Inhibitor Action (2003) (2)
- Abstract PD2-04: FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer (2017) (1)
- Die and let live: harnessing BikDD to combat breast cancer stem cells (2012) (1)
- Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models (2021) (1)
- Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer (2021) (1)
- Abstract 376: Therapeutic role of ESR1-CCDC170 gene fusion in breast cancer endocrine resistance (2019) (1)
- Non-nuclear human estrogen receptor-alpha 36 (hERα-36) is expressed in ER, PR, and Her2 positive or negative breast cancer patients as well as cell lines, and physically interacts with Her2 (2008) (1)
- ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine therapy (ET): A retrospective analysis of the ALTERNATIVE and SOLTI-PAMELA trials (2019) (1)
- Abstract PD2-05: Evaluating the role of recurrent ESR1-CCDC170 in breast cancer endocrine resistance (2016) (1)
- Author Correction: Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance (2020) (1)
- Abstract 1077: Acquired neratinib resistance is associated with acquisition ofHER2andPIK3CAmutations and can be overcome using potent drug combinations in HER2-positive breast cancer models (2021) (1)
- Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors (2012) (1)
- Subtype of Breast Tumor Xenografts Transforms the Clinically Associated Molecular Profile Development of Resistance to Targeted Therapies (2008) (1)
- Abstract P6-09-02: Effects of palbociclib on thymidine kinase-1 (TK1) in hormone receptor positive (HR+) breast cancer cell lines (2019) (1)
- Abstract P2-02-07: Collection, high-resolution imaging, and single cell isolation of circulating tumor cells from patient derived xenograft models using the AccuCyte® – CyteFinder® system (2016) (1)
- Erratum to Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells (Cell Cycle, 14, 4 (648-655), 10.4161/15384101.2014.994966) (2015) (1)
- Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer (2021) (1)
- Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells (2015) (1)
- Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib in HER2 Positive Breast Cancers: Role of ER and HER2 Reactivation. (2009) (1)
- Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC). (2016) (1)
- Abstract P6-04-25: Genomic Deregulation and Therapeutic Role of Nemo-like Kinase in Luminal B Breast Cancer (2012) (1)
- Abstract P4-06-02: Identification of novel G-protein coupled receptor targets in HER2-positive breast cancer. (2012) (1)
- P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer. (2011) (1)
- The Importance of Estrogen Receptors in Breast Cancer (2008) (1)
- A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer (2022) (1)
- Abstract P4-04-03: Hyperactive FOXA1 activates super-enhancer-engaged HIF2α/EPAS1 to promote endocrine-resistant metastatic ER-positive breast cancer (2018) (1)
- The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance (2018) (1)
- Author Correction: Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance (2020) (1)
- Abstract LB517A: The role of EGFR in resistance to tucatinib and its therapeutic implications (2022) (1)
- Calibrating the imaging and therapy performance of magneto-fluorescent gold nanoshells for breast cancer (2012) (1)
- Mirnas: Small molecules, big players in tamoxifen resistance in breast cancer (2012) (1)
- Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8 (2015) (1)
- Abstract SP139: HER2 targeted therapy: Determinants of response and mechanisms of resistance (2021) (1)
- Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models (2021) (1)
- P3-03-05: Identification of miRNAs and Their Associated Target Genes Involved in Endocrine Resistance in Breast Cancer. (2011) (1)
- Reduction in Nanoparticle Size Dramatically Improves Plasmonic Photo-thermal Therapy Efficacy in Aggressive Triple Negative Breast Cancer (2014) (1)
- Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies (2018) (1)
- In vivo longitudinal imaging of RNA interference‐induced endocrine therapy resistance in breast cancer (2019) (1)
- Elacestrant and the Promise of Oral SERDs. (2022) (1)
- A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2‐positive breast cancer (2021) (1)
- Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase (2014) (1)
- Resistance to endocrine therapy in breast ogen receptor / growth factor signaling crosstalk (2007) (0)
- Abstract P1-07-07: Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers (2015) (0)
- Abstract ES7-3: ES7-3 Mechanisms of resistance to Her2 positive disease (2017) (0)
- 69P Impact of statin use on survival outcomes of patients with HER2-positive early breast cancer in the APHINITY trial (2022) (0)
- Abstract PD09-08: The potential role of TLK2 as a therapeutic target in breast cancer. (2012) (0)
- Abstract 3032: Genomic deregulation and therapeutic role of the cell-cycle kinase TLK2 in more aggressive breast cancers (2015) (0)
- Abstract P3-04-04: Amplification and overexpression of TLK2 promote genomic instability in invasive breast cancer (2013) (0)
- PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells (2017) (0)
- Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer (2018) (0)
- Abstract 3508: FOXA1 genetic alterations in whites versus blacks or African Americans in breast and prostate cancer (2020) (0)
- Abstract 4757: Targeting the mevalonate pathway in HER2+breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy (2019) (0)
- Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer (2020) (0)
- Targeting GPR110 in HER2-Overexpressing Breast Cancers (2015) (0)
- Microscaled proteogenomic methods for precision oncology (2020) (0)
- Abstract P4-15-05: Biomarkers of response to neoadjuvant endocrine therapy with anastrozole (Ana) alone or in combination with fulvestrant (Ful) in ER-positive (ER+) HER2-negative (HER2-) breast cancer (PACT01 trial) (2019) (0)
- Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance (2020) (0)
- Abstract P6-05-12: Lack of Frequent Estrogen Receptor Mutation in Primary Breast Tumors (2012) (0)
- Abstract P5-09-20: Development of a novel selective estrogen receptor down-regulator which shows efficacy in pre-clinical models of endocrine resistance (2013) (0)
- Crosstalk between PARP-1 and NF-κB signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines. (2015) (0)
- Abstract P3-04-07: The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy (2017) (0)
- Estrogen Receptor Genomic Function Factor Receptor Signaling with Repression of Classic Tamoxifen Resistance in Breast Tumors Is Driven by Growth (2008) (0)
- Abstract A62: PARP-1 regulates NF-κB-mediated IL-8 expression in HER2 positive breast cancer (2015) (0)
- Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial. (2022) (0)
- DE-ESCALATING TREATMENT FOR HER2-POSITIVE EARLY BREAST CANCER. (2020) (0)
- Abstract 3044: The role of GPR110 in tumorigenicity, tumor cell dissemination, and cell cycle regulation in HER2+ breast cancer (2019) (0)
- 46PMetabolomic analysis as a tool to identify breast cancer (BC) cell lines resistant to palbociclib (PD) (2017) (0)
- Abstract 1223: Evaluation of the dual p38/NLK kinase inhibitor as potential new therapeutic agent for tamoxifen-resistant breast cancer (2017) (0)
- Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators? (2006) (0)
- 658 An essential role for AIB1 phosphorylation in tamoxifen resistance (2004) (0)
- Abstract S6-10: Identification of a Novel Tumor Suppressor Network Reveals a Role for Proto-Oncogenic Receptor Tyrosine Kinases in Triple-Negative Breast Cancer (2010) (0)
- Abstract PD8-06: Acquired resistance to tucatinib is associated with EGFR amplification in HER2+ breast cancer (BC) models and can be overcome by a more complete blockade of HER receptor layer (2022) (0)
- Abstract P4-02-20: Plasticity of the ER and HER2 Signaling Networks Results in Compensatory Escape Pathways Contributing to Treatment Resistance (2010) (0)
- ADGRF1 signaling pathways in Breast Cancer (2020) (0)
- Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis (2015) (0)
- P4-07-03: Identification of Triple-Negative Primary Breast Cancer Xenograft Models with High Numbers of Circulating and Disseminated Tumor Cells. (2011) (0)
- Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models (2015) (0)
- Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis (2019) (0)
- Abstract P6-11-01: A broad spectrum therapeutic strategy for TNBC revealed by a new pathway that coordinates oncogenic RTKs (2015) (0)
- Abstract 3573: Novel G protein-coupled receptor targets in HER2+ breast cancer (2015) (0)
- Abstract P6-20-10: Role of GPR110 in breast cancer (2019) (0)
- Kidney Cell Tumorigenesis Counterbalancing Isoform Coactivator Modulator in Human Dual Roles for Coactivator Activator and its (2008) (0)
- Vandetanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (HER1), Potentiates Anti-Tumor Effects of Combined Endocrine and Trastuzumab Treatment in Estrogen Receptor-Positive (ER+)/HER2-Overexpressing Xenografts. (2009) (0)
- P4-01-02: Endocrine Resistance: Mechanism, Tumorigenic Capacities, and New Therapeutic Strategies. (2011) (0)
- Abstract 1926: Npy1r as a prognostic marker and a novel drug target in estrogen receptor-positive breast cancer (2018) (0)
- Combination antiHER therapeutics — efficacy of alternative dosing regimens in ER+/HER2+ breast cancer xenografts. (2009) (0)
- Abstract 5238: Acquired therapeutic resistance is mediated by deregulation of multiple pathways. (2013) (0)
- Abstract P5-05-01: Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance (2015) (0)
- Abstract P3-06-03: Dual p38/NLK kinase inhibitor as potential novel therapeutic agent for tamoxifen-resistant luminal breast cancer (2018) (0)
- Abstract P3-06-07: ADGRF1 overexpression inhibits tumor growthin vivoby inducing cell cycle arrest in HER2+ breast cancer (2020) (0)
- Abstract 3012: Single-cell transcriptomic characterization of luminal breast cancer cell lines with acquired resistance to the CDK4/6 inhibitor palbociclib (2019) (0)
- AWARD NUMBER: W81XWH-14-1-0326 TITLE: Overcoming Endocrine Resistance by Targeting ER/FoxA1/IL-8 Axis PRINCIPAL INVESTIGATOR: Xiaoyong Fu CONTRACTING ORGANIZATION: Baylor College of Medicine (2016) (0)
- Abstract 737: Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance (2015) (0)
- Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer (2020) (0)
- Abstract P2-06-09: Mucin4 Is Associated with the Loss of Estrogen-Receptor-α in Breast Cancer (2010) (0)
- Abstract 721: Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+ breast cancer (2015) (0)
- Erratum (2015) (0)
- Abstract 738: Combined inhibition of non-canonical HER2 signaling as a strategy to overcome resistance to HER2-targeted therapies (2015) (0)
- Abstract P6-10-03: The PKC inhibitor PKC412 antagonizes breast cancer cell growth and enhances tamoxifen sensitivity (2012) (0)
- Breast tumor xenografts of luminal subtype switch to the ERBB2+ molecular subtype in response to endocrine therapy: Gene expression profiling may not predict pathways of resistance in pretreatment tumors (2007) (0)
- Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells (2015) (0)
- Abstract 3926: Abrogating tamoxifen resistance with the ribonucleoside analog, 8-amino adenosine (2012) (0)
- S07 Overcoming resistance to endocrine therapies: Multiple interventions to reach the goal (2011) (0)
- PG 7.03 The changing role of ER in endocrine resistance (2015) (0)
- Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer (2021) (0)
- Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models (2023) (0)
- Abstract S5-8: Parallel upregulation of Bcl2 and estrogen receptor (ER) expression in HER2+ breast cancer patients treated with neoadjuvant lapatinib. (2012) (0)
- Abstract P2-08-06: Standardized nCounter-based determination of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor status in breast cancer (2019) (0)
- Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer (2020) (0)
- Abstract P4-03-04: Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy (2018) (0)
- Abstract P6-02-07: Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib (2017) (0)
- Abstract MS1-1: Oncogene signal transduction and antiestrogen resistance (2023) (0)
- Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer (2023) (0)
- Abstract 2290: Crosstalk between ER and PI3K signaling pathways in human luminal type breast cancer and its therapeutic implications (2011) (0)
- P4-01-03: Establishment and Characterization of an Endocrine Resistance Model In Vitro and In Vivo by Inducible PTEN Knockdown. (2011) (0)
- Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer (2022) (0)
- Abstract 4827: The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positivein vivobreast cancer models (2019) (0)
- Abstract P2-09-08: Therapeutic potential of the dual HER1/2 inhibitor AZD8931 in circumventing endocrine resistance (2013) (0)
- Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC) (2021) (0)
- Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination (2015) (0)
- Abstract 2783:OMICSanalysis of breast cancer PDX tumors to determine CTC-cluster-specific signature in predicting breast cancer metastasis (2019) (0)
- Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery (2021) (0)
- Abstract 376: Therapeutic role ofESR1-CCDC170gene fusion in breast cancer endocrine resistance (2019) (0)
- Abstract 5741: Evaluating the role of recurrentESR1-CCDC170fusion in breast cancer endocrine resistance (2017) (0)
- S20 Combined ER and HER-targeted therapy in breast cancer treatment (2009) (0)
- Abstract P4-01-01: Resistance to next generation tyrosine kinase inhibitors (TKIs) in HER2-positive breast cancer (BC): Role of HER and PIK3CA mutations and development of new treatment strategies and study models (2022) (0)
- Abstract LB-305: Circulating tumor cells as a novel model to test efficacy of individualized therapy in breast cancer (2012) (0)
- Die and let live: harnessing BikDD to combat breast cancer stem cells (2012) (0)
- Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance (2019) (0)
- Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC) (2023) (0)
- Abstract P6-04-05: GPR110 overexpression increases tumorigenic potential of HER2+ breast cancer cells (2013) (0)
- Abstract 4474: Novel neoplastic RAD51AP1-DYRK4 fusion transcript in aggressive luminal breast cancers (2019) (0)
- Abstract P6-17-12: Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positivein vivobreast cancer models (2019) (0)
- Clonal Evolution of the HER2 L755S Mutation Leads to Acquired HER‐targeted Therapy Resistance That Can Be Reversed by the Irreversible HER1/2 Inhibitor Afatinib (2015) (0)
- Abstract 3969: CTCs and CTC clusters in breast cancer patient-derived xenograft models (2016) (0)
- P1-08-04: Obesity, Adjuvant Therapy, and Survival Outcomes in Early-Stage Breast Cancer. (2011) (0)
- Abstract B078: FOXA1 genetic alterations in Whites versus Blacks or African Americans in breast and prostate cancer (2020) (0)
- Cell type and development specifications of murine retrotransposon expression (1989) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Rachel Schiff?
Rachel Schiff is affiliated with the following schools:
